Catabasis Pharmaceuticals
| Region | Nordamerika |
| ISIN | US14875P2065 |
| Sektor | Biotechnologie |
| Website | https://www.catabasis.com/ |
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com or www.twitter.com/catabasispharma.
| Titel | Autor | Datum |
|---|---|---|
|
Der Tenbagger-Kandidat für 2020!
|
sharedeals | vor ungefähr 6 Jahren |
|
Der heißeste Buyout-Kandidat des Jahres!
2 Kommentare |
sharedeals | vor ungefähr 7 Jahren |
| Titel | Datum |
|---|---|
| MISC to charter two more LNG carriers for PETRONAS LNG | vor 23 Tagen |
| MISC FY2025 Profit Up 43% To RM1.7 Billion Despite Revenue Slump | vor 29 Tagen |
| MISC declares 14 sen dividend as 4Q loss narrows on better operating income, lower impairments | vor 29 Tagen |
| MISC secures long-term FSO charter for Papua New Guinea LNG supply chain | vor ungefähr einem Monat |
| Nestlé Malaysia, Bina Puri, FBG, Atlan, MISC, Jentayu Sustainables, IHH | vor ungefähr einem Monat |
| Diese Aktien könnten Dich auch interessieren | |
|---|---|
| Cannabis Wheaton Income (2 Artikel) | |
| BYD Company (1 Artikel) | |
| CBLT (1 Artikel) | |
| Celgene (1 Artikel) | |
| Alle anzeigen | |